The ECEL1 Knockout K-562 Polyclonal Cells are a heterogeneous CRISPR/Cas9-edited polyclonal knockout cell population generated by disrupting the ECEL1 gene in the K-562 human chronic myelogenous leukemia (CML) lymphoblast cell line. This pool of edited cells provides a robust loss-of-function model for investigating ECEL1 metalloprotease activity and its role in neuropeptide processing, without the constraints of single-cell cloning. The polyclonal format preserves genetic diversity across the population, enabling screening applications and functional genomics studies.
The parental K-562 cell line was established from the pleural effusion of a patient with chronic myelogenous leukemia in blast crisis. These cells are characterized by the Philadelphia chromosome (t(9;22) translocation) leading to expression of the BCR-ABL fusion protein, which drives uncontrolled proliferation. K-562 is widely used as a model for hematopoietic differentiation, apoptosis, and signal transduction, and its rapid growth and amenability to transfection make it a versatile platform for gene editing and high-throughput assays.
ECEL1 encodes an endopeptidase that selectively cleaves neuropeptide precursors, including substance P, bradykinin, and neurotensin, to generate bioactive peptides. In neuronal and neuromuscular contexts, ECEL1 activity is transcriptionally regulated by neurogenic factors such as NEUROG and ASCL1, and is modulated by Notch signaling. The enzyme resides in the endoplasmic reticulum and interacts with ER chaperones and protein disulfide isomerase to ensure proper folding and activity. Downstream, processed neuropeptides act on GPCRs to trigger Ca2? and ERK signaling cascades essential for neuronal function and neuromuscular junction development.
In the K-562 background, ECEL1 knockout provides a clean cellular system to investigate metalloprotease-mediated neuropeptide maturation independent of neuronal differentiation signals that normally dominate in primary neuron models. Although K-562 is of hematopoietic origin, its well-characterized signaling networks and ease of genetic manipulation allow for precise dissection of ECEL1 biochemistry, substrate specificity, and interaction partners. This model is particularly valuable for studying how neuropeptide processing defects contribute to disorders like distal arthrogryposis type 5D and congenital contractures, without the confounding influence of developmental cues.
Researchers can employ these knockout cells in a range of assays: western blotting and RT-qPCR to confirm target disruption, fluorogenic peptidase assays to quantify loss of enzyme activity, and neuropeptide cleavage assays using synthetic substrates to profile residual processing. The polyclonal pool is ideal for CRISPR knockout screens, RNA-seq to map transcriptomic changes, and differentiation assays if combined with neural induction protocols. Furthermore, the model supports drug discovery efforts aimed at modulating neuropeptide signaling pathways. For more information or custom requests, please contact Ascent Research.
